These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 18018763

  • 1. The association of bone mineral density with HIV infection and antiretroviral treatment in women.
    Anastos K, Lu D, Shi O, Mulligan K, Tien PC, Freeman R, Cohen MH, Justman J, Hessol NA.
    Antivir Ther; 2007; 12(7):1049-58. PubMed ID: 18018763
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):191-7. PubMed ID: 16886959
    [Abstract] [Full Text] [Related]

  • 3. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
    Kwak MK, Lee EJ, Park JW, Park SY, Kim B-, Kim TH, Suh K, Koh J-, Lee SH, Byun D-.
    Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
    [Abstract] [Full Text] [Related]

  • 4. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
    Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS.
    PLoS One; 2015 Jul; 10(12):e0144286. PubMed ID: 26633015
    [Abstract] [Full Text] [Related]

  • 5. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
    Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J.
    HIV Med; 2011 Mar; 12(3):157-65. PubMed ID: 20722752
    [Abstract] [Full Text] [Related]

  • 6. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.
    Nolan D, Upton R, McKinnon E, John M, James I, Adler B, Roff G, Vasikaran S, Mallal S.
    AIDS; 2001 Jul 06; 15(10):1275-80. PubMed ID: 11426072
    [Abstract] [Full Text] [Related]

  • 7. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM, Wattanachanya L, Apornpong T, Jantrapakde J, Avihingsanon A, Kerr SJ, Teeratakulpisarn N, Jadwattanakul T, Chaiwatanarat T, Buranasupkajorn P, Ramautarsing R, Phanuphak N, Sunthornyothin S, Ruxrungtham K, Phanuphak P, TNT 003.1 study team.
    PLoS One; 2020 Jul 06; 15(3):e0230368. PubMed ID: 32210458
    [Abstract] [Full Text] [Related]

  • 8. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS.
    Zhonghua Nei Ke Za Zhi; 2010 Aug 06; 49(8):649-52. PubMed ID: 20979781
    [Abstract] [Full Text] [Related]

  • 9. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA.
    HIV Clin Trials; 2003 Aug 06; 4(5):337-46. PubMed ID: 14583850
    [Abstract] [Full Text] [Related]

  • 10. Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.
    Zhang L, Su Y, Hsieh E, Xia W, Xie J, Han Y, Cao Y, Li Y, Song X, Zhu T, Li T, Yu W.
    BMC Musculoskelet Disord; 2013 Jul 30; 14():224. PubMed ID: 23899016
    [Abstract] [Full Text] [Related]

  • 11. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, Mannazzu M, Nuvoli S, Piras B, Bagella P, Mura MS, Madeddu G.
    Eur Rev Med Pharmacol Sci; 2015 Dec 30; 19(23):4576-89. PubMed ID: 26698255
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.
    Cervero M, Torres R, Agud JL, Alcázar V, Jusdado JJ, García-Lacalle C, Moreno S.
    PLoS One; 2018 Dec 30; 13(4):e0196201. PubMed ID: 29709013
    [Abstract] [Full Text] [Related]

  • 13. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    Clin Endocrinol (Oxf); 2007 Aug 30; 67(2):270-5. PubMed ID: 17547686
    [Abstract] [Full Text] [Related]

  • 14. Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.
    Vlot MC, Grijsen ML, Prins JM, de Jongh RT, de Jonge R, den Heijer M, Heijboer AC.
    PLoS One; 2018 Aug 30; 13(3):e0193679. PubMed ID: 29522570
    [Abstract] [Full Text] [Related]

  • 15. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G.
    Q J Nucl Med Mol Imaging; 2004 Mar 30; 48(1):39-48. PubMed ID: 15195003
    [Abstract] [Full Text] [Related]

  • 16. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.
    Lo Re V, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, Zirilli L, Rochira V, Kostman JR, Tebas P.
    AIDS; 2009 Oct 23; 23(16):2191-8. PubMed ID: 19779322
    [Abstract] [Full Text] [Related]

  • 17. Long-term use of protease inhibitors is associated with bone mineral density loss.
    Kinai E, Nishijima T, Mizushima D, Watanabe K, Aoki T, Honda H, Yazaki H, Genka I, Tanuma J, Teruya K, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.
    AIDS Res Hum Retroviruses; 2014 Jun 23; 30(6):553-9. PubMed ID: 24494779
    [Abstract] [Full Text] [Related]

  • 18. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
    Hoy JF, Grund B, Roediger M, Schwartz AV, Shepherd J, Avihingsanon A, Badal-Faesen S, de Wit S, Jacoby S, La Rosa A, Pujari S, Schechter M, White D, Engen NW, Ensrud K, Aagaard PD, Carr A, INSIGHT START Bone Mineral Density Substudy Group.
    J Bone Miner Res; 2017 Sep 23; 32(9):1945-1955. PubMed ID: 28650589
    [Abstract] [Full Text] [Related]

  • 19. Continuous antiretroviral therapy decreases bone mineral density.
    Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD, INSIGHT SMART Body Composition Substudy Group.
    AIDS; 2009 Jul 31; 23(12):1519-29. PubMed ID: 19531929
    [Abstract] [Full Text] [Related]

  • 20. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
    Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J.
    AIDS; 2003 Sep 05; 17(13):1917-23. PubMed ID: 12960824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.